RDB07827 - pGL3-AID R1 del.-04

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pGL3-AID R1 del.-04 (#RDB07827)

Reporter construct of mouse Aicda locus, position -839 to +101.

Clone info.	Reporter construct of mouse Aicda locus with firefly luciferase. Cloned position, -839 to +101.
Comment	Nat. Immunol. (2010) 2, 148-154, Fig. 1a.
Vector backbone	pGL3 (Plasmid)
Selectable markers	Amp^r
Gene/insert name	Mouse Aicda genomic DNA
Depositor\|Developer	Honjo, Tasuku \|

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
MTA, for use for for-profit purpose [Word]
Please visit Information of Request for Distribution.[link]

Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature(s) designated by the DEPOSITOR is requested. (Nat. Immunol., 11, 148-154 (2010)). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
Additional terms and conditions:
The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] MTA, for use for for-profit purpose [Word] Please visit Information of Request for Distribution.[link]
Terms and conditions for distribution	In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature(s) designated by the DEPOSITOR is requested. (Nat. Immunol., 11, 148-154 (2010)). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 提供同意書 (MTA, 営利目的用)[Word] 手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件	利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Nat. Immunol., 11, 148-154 (2010))。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。　学術機関の学術研究に限る。　営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。　利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 MTAに書く付加的使用条件：本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

必要書類

提供依頼書

[依頼書の記入例

]
提供同意書 (MTA, 非営利学術目的用)[Word

] [MTAの記入例

]
提供同意書 (MTA, 営利目的用)[Word

]
手続きの概要は、「提供申込みについて[link]」をご覧ください。

MTAに書く使用条件

利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Nat. Immunol., 11, 148-154 (2010))。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。　学術機関の学術研究に限る。　営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。　利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。
MTAに書く付加的使用条件：
本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB07827	pGL3-AID R1 del.-04	DNA solution	JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pGL3-AID R1 del.-04 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07827).

Reference section:

Tran, T.H., Nakata, M., Suzuki, K., Begum, N.A., Shinkura, R., Fagarasan, S., Honjo, T., Nagaoka, H., B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat. Immunol., 11, 148-154 (2010). PMID 19966806. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB07827_A4Gi.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: pGL4-4174F Sequence file: RDB07827_A4Gia.seq
>07827_07827_A4Gi_pGL4-4174F_D11_11.ab1 1 AGGAGGGGTC CAGAAATTTC TCTATCGATA GGTACCGAGC TCTTACGCGT GCTAGCCCGG 61 GCTCGAGTGA TCAGGGTTCA GATCCCAGCA AGCACACATG GTGGCTTTCA ACTGCCTGCT 121 GGTCCTCTGC AATAGAAGTA AGTGCTCTTA ATCACTGGGC CAGCTCTCCA GGCCTCCAGT 181 AAGGTATTTT TAATGAGGAA AAGGAGTTCT TTTTTTTTTT AATACTTTTT GACACACACA 241 CACACACAAA ATTAAAATAA ATCACTTTTT GGTGCAAGCA ACTAGTCTTT CTAGCTATCT 301 TATAATGTCA TTTTAAAAAA AGAAAAATAT ATTAGAGAAT TGGGAGGCTA AAGTTCACTC 361 TCTGGATGCT GTGGTGGTCA ACCCCCATCT CTACTGAGGC ATAAAACTGA GTGTAACAAA 421 CGGAAGGAAC AGATACTGTA AGTTCAAGAA GCACAAGATG CAACTGAAGT GCCATTTAAG 481 GCCACTTTAA GTCACTATGA CTGCTATCAT TCTTGTTATC ATAGTTTTAA AATTAGGAAG 541 TATGCACAGA CCTTAGGTGT GATACCCGGG ACCACACACA CACACACACA CACACACTCA 601 CAGAGCTCAT TATCATGATA CCAATGTGAG AAGTGTCCAG TGCTATTGTC TCCTGATCTT 661 TGTTACCTGT GATACCTGGG CTGGCTTTTT AGAGGAACAG CCTCGAAGGA AGTTGGACAT 721 TAAGCATGAG CAGAACTGGC CCCCCCCCCC AATCATTTAA TCCGTGTGGC TTTGCCCACC 781 ACAGCCCCGC CCATCTTTAC TGGACCCAAC CCAGGAGGCA GATGTTGGAT ACCTGGTGGT 841 AGTGATGCTG TCGTGGGGGA GGAGCCCACA AGAGCAAGCT CAGATTTGAA TGCCAGGGGC 901 CAGTGCTCTG TCACACAACA GCACTGAAGC AGCCTTGCTT GAAGCAAGCT TCCTTTGGCC 961 TAAGACTTTG AGGGAGTCAA GAAAGTCACG CTGGGAGACC GATCCATGGA AGACGCCCAA 1021 AAACATAAAG AAAGGCCCGG GCGCCAATTC TATCCGCTGA GATGGGAAAC CGCTGGGAGA 1081 GCACTGCATA AGCTTATGAG AGAATACGCC CTGGATCTGA CCATTGCTTT ACAGATGCAC 1141 AATAATTCGA AGGGTGGCA //
Primer: Luc_R Sequence file: RDB07827_A4Gib.seq
>07827_07827_A4Gi_Luc_R_E11_14.ab1 1 CATTGCTTCA GGGACCAGGG CGTATCTCTT CATAGCCTTA TGCAGTTGCT CTCCAGCGGT 61 TCCATCTTCC AGCGGATAGA ATGGCGCCGG GCCTTTCTTT ATGTTTTTGG CGTCTTCCAT 121 GGATCGGTCT CCAGCGTGAC TTTCTTGACT CCCTCAAAGT CTTAGGCCAA AGGAAGCTTG 181 CTTCAAGCAA GGCTGCTTCA GTGCTGTTGT GTGACAGAGC ACTGGCCCCT GGCATTCAAA 241 TCTGAGCTTG CTCTTGTGGG CTCCTCCCCC ACGACAGCAT CACTACCACC AGGTATCCAA 301 CATCTGCCTC CTGGGTTGGG TCCAGTAAAG ATGGGCGGGG CTGTGGTGGG CAAAGCCACA 361 CGGATTAAAT GATTGGGGGG GGGGGCCAGT TCTGCTCATG CTTAATGTCC AACTTCCTTC 421 GAGGCTGTTC CTCTAAAAAG CCAGCCCAGG TATCACAGGT AACAAAGATC AGGAGACAAT 481 AGCACTGGAC ACTTCTCACA TTGGTATCAT GATAATGAGC TCTGTGAGTG TGTGTGTGTG 541 TGTGTGTGTG TGGTCCCGGG TATCACACCT AAGGTCTGTG CATACTTCCT AATTTTAAAA 601 CTATGATAAC AAGAATGATA GCAGTCATAG TGACTTAAAG TGGCCTTAAA TGGCACTTCA 661 GTTGCATCTT GTGCTTCTTG AACTTACAGT ATCTGTTCCT TCCGTTTGTT ACACTCAGTT 721 TTATGCCTCA GTAGAGATGG GGGTTGACCA CCACAGCATC CAGAGAGTGA ACTTTAGCCT 781 CCCAATTCTC TAATATATTT TTCTTTTTTT AAAATGACAT TATAAGATAG CTAGAAAGAC 841 TAGTTGCTTG CACCAAAAAG TGATTTATTT TAATTTTGTG TGTGTGTGTG TGTCAAAAAG 901 TATTAAAAAA AAAAAGAACT CCTTTTCCTC ATTAAAAATA CCTTACTGGG AGGGCCTGGA 961 GAGCTGGCCC AGTGATTAAA GAGCACTTAC TTCTATTGCA GAGGACCAGC AGGCAGTTGA 1021 AGCCACCATG GTGGTGCTTT GCTGGGATCT GACCCCTGAT CACTCGGAGG CCCGGACTAG 1081 CACGGCGTAG GAGCTCGGCT ACTATCGATT AGAGAAATTG ATCCTGGGCA CCTGGCAACG 1141 TTGCACCTGG GGGGACAG //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original	Tran, T.H., B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat. Immunol., 11, 148-154 (2010). PMID 19966806. [link to RRC of NBRP]

Resource search

Link

Other resources in our bank

mouse Aicda

External Database
Mouse Aicda

Reference sequence